DA
EW icon

Dunvegan Associates’s Edwards Lifesciences EW Stock Holding History

Dunvegan Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$11K Hold
420
– – 0.01% 159
2015
Q3 		$10K Hold
420
– – 0.01% 162
2015
Q2 		$10K Hold
420
– – 0.01% 158
2015
Q1 		$10K Hold
420
– – 0.01% 167
2014
Q4 		$9K Hold
420
– – 0.01% 170
2014
Q3 		$7K Hold
420
– – 0.01% 173
2014
Q2 		$6K Hold
420
– – 0.01% 180
2014
Q1 		$5K Buy
+420
New +$4.85K ﹤0.01% 197

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $29.1B AUM 43.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Dunvegan Associates's EW Position: Q4 2015 in Review

Dunvegan Associates held its Edwards Lifesciences (EW) position steady in Q4 2015 at 420 shares worth $11K. The position accounts for 0.01% of the portfolio, ranked #159.

Dunvegan Associates first reported a position in EW in Q1 2014 and has held it in 8 quarters since. 605 funds tracked by Wall St. Rank hold EW as of Q4 2015.

  • Dunvegan Associates held 420 shares of Edwards Lifesciences worth $11K as of Q4 2015.
  • Dunvegan Associates left its Edwards Lifesciences share count unchanged in Q4 2015.
  • Edwards Lifesciences made up 0.01% of Dunvegan Associates's portfolio in Q4 2015, its #159 holding.
  • Dunvegan Associates first reported a position in Edwards Lifesciences in Q1 2014 and has held it in 8 quarters since.
  • 605 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2015.

Based on Dunvegan Associates's 13F filing for Q4 2015, filed 28 Apr 2017.